Overview

Anakinra (Kineret) is a recombinant IL-1 receptor antagonist that blocks the activity of interleukin-1 alpha and beta.

Mechanism of Action

IL-1 receptor blockade — Competitively inhibits IL-1α and IL-1β binding
Anti-inflammatory — Reduces systemic and local inflammation
Autoimmune modulation — Controls inflammatory cascades in RA and CAPS

Dosing

100mg subcutaneously once daily for rheumatoid arthritis. Higher doses (1-2mg/kg) for CAPS.

Indications

FDA-approved for: Rheumatoid arthritis (adults), Cryopyrin-associated periodic syndromes (neonatal-onset multisystem inflammatory disease), Still's disease.

Safety

FDA-approved. Monitor for neutropenia and serious infections. Injection site reactions common.